Summit’s Ivonescimab Delivers First Major PFS Win in EGFR-Mutated Lung Cancer After TKI Failure
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.
/ 185 items
#XY Analyst Up/Down↓
Wall Street Turns Bullish on Capricor as FDA Extends Review for Deramiocel to November
Oppenheimer raises Capricor to Outperform on clearer path for deramiocel. $54 target, PDUFA Nov 22 after upper-limb focus.
Wolfe Research Upgrades Moderna to Peer Perform After Cancer Vaccine Breakthrough
Wolfe Research upgrades Moderna to Peer Perform following Phase 3 intismeran success and a potential $9.2 billion peak sales outlook.
Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Wolfe Research Upgrades Janux Therapeutics to Outperform on Upcoming Autoimmune Data
Wolfe Research upgrades Janux Therapeutics to Outperform with a $23 target. Q4 autoimmune data for JANX011 cited as key catalyst, 32% upside.
Morgan Stanley Initiates Q32 Bio at Overweight with $34 Target — 113% Upside Potential
Morgan Stanley initiates Q32 Bio at Overweight ($34 target) as bempikibart matches JAK efficacy in alopecia areata while offering cleaner safety, less monitoring and durability.